Rationale and design of a randomised phase II multicentre crossover trial investigating a sodium-glucose co-transporter 2 inhibitor, dapagliflozin, combined with a novel continuous ketone monitor in adults with type 1 diabetes to reduce the risk of diabetic ketoacidosis: the PARTNER study. - Ngan J; Kong YW; Goad J; Huang MLH; Jenkins A; Vogrin S; Trawley S; Manzoney A; Nakano M; Ekinci E; Kriketos A; Fourlanos S; et al. (BMJ open, 2025)